logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

C ZENITH CHEM (00362) appoints Zeng Qianning as non-executive director.

date
21:44 07/01/2025
avatar
GMT Eight
China Tianhua Group (00362) announced that Ms. Zeng Qianning has been appointed as a non-executive director, effective January 7, 2025...
C ZENITH CHEM(00362) announced that Ms. Zeng Qianning has been appointed as the non-executive director, effective from January 7, 2025. Mr. Ma Jianling has resigned as the company secretary, chief financial officer, and legal representative, effective from December 31, 2024.
Related Articles
HK Stock
Eve's Intelligence (03696) completed the first subject dosing of GARUTADUSTAT (ISM5411) in the Phase IIa clinical trial called BETHESDA.
HK Stock
HASHKEY HLDGS(03887): Partial exercise of the excess rights issue, stabilization actions and the end of the price stabilization period.
Hong Kong Stock Concept Tracking| AI Infrastructure Expansion Drives Copper Demand Growth Institutions Bullish on Market Continues to Rise (with Concept Stocks)
Eve's Intelligence (03696) completed the first subject dosing of GARUTADUSTAT (ISM5411) in the Phase IIa clinical trial called BETHESDA.
HK Stock
HASHKEY HLDGS(03887): Partial exercise of the excess rights issue, stabilization actions and the end of the price stabilization period.
HK Stock
Hong Kong Stock Concept Tracking| AI Infrastructure Expansion Drives Copper Demand Growth Institutions Bullish on Market Continues to Rise (with Concept Stocks)
RECOMMEND
Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
icon
10/01/2026
Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
icon
10/01/2026
“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
icon
10/01/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.